Abstract

IDEX Corp will report fourth-quarter results on February 04, 2026 Pre-Market, and investors expect modest year-over-year growth in revenue and earnings, with attention on margins and segment mix shifts.

Market Forecast

Consensus for the current quarter points to revenue of $0.88 billion, adjusted EPS of $2.04, and EBIT of $0.19 billion, implying year-over-year revenue growth of 2.15% and a slight adjusted EPS expansion of 1.05%. Forecast detail suggests limited operating leverage with EBIT roughly flat year over year at $0.19 billion, while investors look for gross profit margin stability near the recent 44.52% mark and net profit margin around the mid-teens level; company-level net profit is therefore expected to be broadly steady year over year, and adjusted EPS to improve slightly. Management’s segment outlook emphasizes steady demand in Health & Science Technologies, resilience in Fluid & Metering Technologies, and stable orders in Fire & Safety/Diversified Products. The most promising business remains Health & Science Technologies, which delivered $0.38 billion last quarter and continues to benefit from secular demand in pharma and analytical instrumentation, with expectations for low-single-digit year-over-year growth in the current quarter.

Last Quarter Review

IDEX Corp’s most recent quarter delivered revenue of $0.88 billion, a gross profit margin of 44.52%, GAAP net profit attributable to the parent of $0.13 billion with a net profit margin of 14.54%, and adjusted EPS of $2.03, with revenue rising 10.09% year over year and adjusted EPS growing 6.84% year over year. The quarter’s key highlight was resilient pricing and favorable mix that supported margin stability despite mixed end-market demand. By segment, Health & Science Technologies generated $0.38 billion, Fluid & Metering Technologies produced $0.32 billion, and Fire & Safety/Diversified Products contributed $0.18 billion; Health & Science Technologies continued to outpace peers on normalized demand and project backlog conversion.

Current Quarter Outlook

Health & Science Technologies

Health & Science Technologies remains the company’s largest revenue contributor and a focal point for margin durability. With last quarter revenue of $0.38 billion, the unit benefits from steady consumables-like demand patterns across life sciences, analytical instrumentation, and specialty medical end-markets. The current quarter outlook centers on modest order growth and stable pricing, as customer inventories appear balanced and project funnels support backlog conversion. A key variable to watch is the pace of project awards in bioprocessing and laboratory equipment, which can influence mix and gross profit margin, especially given the company’s past emphasis on higher-value components. If shipments skew toward instrumentation and biopharma tools, gross profit margin near 44.52% looks achievable, supporting an adjusted EPS outcome near the $2.04 consensus. Conversely, any slowing in lab and pharma orders would likely temper volume leverage, keeping EBIT growth near flat as forecast.

Fluid & Metering Technologies

Fluid & Metering Technologies, at $0.32 billion last quarter, shows steady demand across industrial pumps, metering, and process technologies, with a balanced mix between short-cycle replacement and project-driven orders. The quarter’s performance will hinge on order cadence in industrial, water, and energy-related niches, where lead times and pricing discipline have supported margins. In the outlook period, modest price carryover and disciplined cost control should offset normal seasonal slowdowns, suggesting segment margins can hold, even if top-line growth is muted. A gradual improvement in process industries and municipal spending would be a quiet positive, aiding sequential stability in EBIT and supporting the company-wide adjusted EPS forecast of $2.04. Any softness in capital spending from industrial clients could exert pressure on volume, but high attachment rates for aftermarket parts can provide a cushion for revenue quality.

Fire & Safety/Diversified Products

Fire & Safety/Diversified Products contributed $0.18 billion last quarter and remains a smaller but strategically important portfolio for recurring municipal and safety demand. The current quarter’s results are likely to reflect normal seasonality, with stable to slightly softer revenue compared to the immediately prior period. Order patterns in municipal and infrastructure markets, along with international tenders, will influence shipment timing. Pricing in safety and rescue equipment has been holding, and product refresh cycles may support mix, though the quarter-on-quarter growth rate for company-level net profit was negative at -2.89% last quarter, suggesting caution on short-cycle momentum. Investors will monitor whether improved backlog conversion offsets any deferrals in public sector budgets, helping preserve the mid-teens net profit margin range.

Stock Price Drivers This Quarter

Margin trajectory is the central driver: investors will parse gross profit margin relative to the recent 44.52% level and net profit margin relative to 14.54% to gauge pricing power versus cost headwinds. Segment mix is another key factor, as outperformance in Health & Science Technologies tends to carry higher blended margins and support EPS outturns; any skew toward lower-margin industrial orders could cap upside to EBIT. Finally, guidance quality matters: confirmation of low-single-digit revenue growth with disciplined cost control and free-cash-flow conversion can validate the $2.04 adjusted EPS consensus, while commentary that implies slower order intake or less favorable mix would likely lead to estimate resets.

Analyst Opinions

The prevailing tone from sell-side commentary is cautiously bullish, with a higher proportion of positive versus negative views in recent updates. A recent note from Stifel Nicolaus maintained a Buy rating and a $220.00 price target, reflecting confidence in margin resilience and steady execution through mixed end markets. The optimistic camp emphasizes the company’s balanced portfolio and track record of disciplined pricing, which supports expectations for revenue of $0.88 billion, EBIT near $0.19 billion, and adjusted EPS around $2.04 this quarter. These analysts argue that the Health & Science Technologies segment can continue to provide a constructive mix, while operational excellence in Fluid & Metering Technologies underpins stable EBIT despite uneven macro indicators. The cautiousness stems from the -2.89% quarter-on-quarter net profit change last quarter and potential variability in public-sector and industrial orders, though the consensus view is that execution and pricing discipline should sustain mid-teens net margins and incremental EPS growth year over year. Overall, the majority view is to look for modest beats on revenue or EPS if margin mix holds, with any upside likely dependent on stronger-than-expected order intake in higher-margin Health & Science Technologies.